Multicenter, double-blind, randomized, phase II trial to assess the safety and efficacy of ceftolozane-tazobactam plus metronidazole compared with meropenem in adult patients with complicated intra-abdominal infections

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 9, 2014, Pages 5350-5357

  Lucasti, Christopher ^a   Hershberger, Ellie ^b   Miller, Benjamin ^b   Yankelev, Sara ^b   Steenbergen, Judith ^b   Friedland, Ian ^b   Solomkin, Joseph ^c  

^a South Jersey Infectious Disease   (United States)

^b CUBIST PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; CEFTOLOZANE; GAMMA GLUTAMYLTRANSFERASE; MEROPENEM; METRONIDAZOLE; TAZOBACTAM; CEFTOLOZANE, TAZOBACTAM DRUG COMBINATION; CEPHALOSPORIN DERIVATIVE; PENICILLANIC ACID; THIENAMYCIN DERIVATIVE;

ABDOMINAL ABSCESS; ABDOMINAL INFECTION; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANTIMICROBIAL ACTIVITY; APPENDICITIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASPIRATION; CHOLECYSTITIS; CLINICAL EXAMINATION; CONTROLLED STUDY; DEATH; DIARRHEA; DIVERTICULOSIS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DUODENUM PERFORATION; ESCHERICHIA COLI; FEMALE; FEVER; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HOSPITAL PATIENT; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INTENTION TO TREAT ANALYSIS; INTESTINE PERFORATION; KLEBSIELLA PNEUMONIAE; LAPAROSCOPY; LAPAROTOMY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NAUSEA; OUTCOME ASSESSMENT; PERITONITIS; PHASE 2 CLINICAL TRIAL; PHLEBITIS; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT FAILURE; TREATMENT RESPONSE; VOMITING; WOUND DEHISCENCE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG COMBINATION; INTRAABDOMINAL INFECTIONS; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; TREATMENT OUTCOME;

CEPHALOSPORINS; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; INTRAABDOMINAL INFECTIONS; MALE; METRONIDAZOLE; MIDDLE AGED; PENICILLANIC ACID; THIENAMYCINS; TREATMENT OUTCOME;

EID: 84906085321     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00049-14     Document Type: Article

References (31)

1. Solomkin JS, Mazuski JE, Bradley JS, Rodvold KA, Goldstein EJ, Baron EJ, O'Neill PJ, Chow AW, Dellinger EP, Eachempati SR, Gorbach S, Hilfiker M, May AK, Nathens AB, Sawyer RG, Bartlett JG. 2010. Diagnosis and management of complicated intra-abdominal infection in adults and children: guidelines by the Surgical Infection Society and the Infectious Diseases Society of America. Surg. Infect. (Larchmt.) 11:79-109. http://dx.doi.org/10.1089/sur.2009.9930.
2. Babinchak T, Badal R, Hoban D, Hackel M, Hawser S, Lob S, Bouchillon S. 2013. Trends in susceptibility of selected Gram-negative bacilli isolated from intra-abdominal infections in North America: SMART 2005-2010. Diagn. Microbiol. Infect. Dis. 76:379-381. http://dx.doi.org/10.1016/j.diagmicrobio.2013.02.031.
3. Lister PD, Wolter DJ, Hanson ND. 2009. Antibacterial-resistant Pseudomonas aeruginosa: clinical impact and complex regulation of chromosomally encoded resistance mechanisms. Clin. Microbiol. Rev. 22:582-610. http://dx.doi.org/10.1128/CMR.00040-09.
4. Bradford PA. 2001. Extended-spectrum β-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin. Microbiol. Rev. 14:933-951. http://dx.doi.org/10.1128/ CMR.14.4.933-951.2001. (Pubitemid 32979636)
5. Hawser S, Hoban D, Bouchillon S, Badal R, Carmeli Y, Hawkey P. 2011. Antimicrobial susceptibility of intra-abdominal Gram-negative bacilli from Europe: SMART Europe 2008. Eur. J. Clin. Microbiol. Infect. Dis. 30:173-179. http://dx.doi.org/10.1007/s10096-010-1066-0.
6. Hawser SP, Bouchillon SK, Lascols C, Hackel M, Hoban DJ, Badal RE, Woodford N, Livermore DM. 2011. Susceptibility of Klebsiella pneumoniae isolates from intra-abdominal infections and molecular characterization of ertapenem-resistant isolates. Antimicrob. Agents Chemother. 55:3917-3921. http://dx.doi.org/10.1128/AAC.00070-11.
7. Carmeli Y, Akova M, Cornaglia G, Daikos GL, Garau J, Harbarth S, Rossolini GM, Souli M, Giamarellou H. 2010. Controlling the spread of carbapenemase-producing Gram-negatives: therapeutic approach and infection control. Clin. Microbiol. Infect. 16:102-111. http://dx.doi.org/10.1111/j.1469- 0691.2009.03115.x.
8. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Hackel MA, Biedenbach DJ, Goff DA. 2014. Susceptibility of Gram-negative aerobic bacilli from intra-abdominal pathogens to antimicrobial agents collected in the United States during 2011. J. Infect. 68:71-76. http://dx.doi.org/10.1016/j.jinf.2013.09.001.
9. Sader HS, Rhomberg PR, Farrell DJ, Jones RN. 2011. Antimicrobial activity of CXA-101, a novel cephalosporin tested in combination with tazobactam against Enterobacteriaceae, Pseudomonas aeruginosa, and Bacteroides fragilis strains having various resistance phenotypes. Antimicrob. Agents Chemother. 55:2390-2394. http://dx.doi.org/10.1128/AAC.01737-10.
10. Titelman E, Karlsson IM, Ge Y, Giske CG. 2011. In vitro activity of CXA-101 plus tazobactam (CXA-201) against CTX-M-14- and CTX-M-15-producing Escherichia coli and Klebsiella pneumoniae. Diagn. Microbiol. Infect. Dis. 70:137-141. http://dx.doi.org/10.1016/j.diagmicrobio.2011.02.004.
11. Livermore DM, Mushtaq S, Ge Y. 2010. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus β-lactamase- producing Enterobacteriaceae. J. Antimicrob. Chemother. 65:1972-1974. http://dx.doi.org/10.1093/jac/dkq248.
12. Farrell DJ, Flamm RK, Sader HS, Jones RN. 2013. Antimicrobial activity of ceftolozane/tazobactam tested against Enterobacteriaceae and Pseudomonas aeruginosa with various resistance patterns isolated in U.S. hospitals (2011-2012). Antimicrob. Agents Chemother. 57:6305-6310. http://dx.doi.org/10. 1128/AAC.01802-13.
13. Walkty A, Karlowsky JA, Adam H, Baxter M, Lagace-Wiens P, Hoban DJ, Zhanel GG. 2013. In vitro activity of ceftolozane-tazobactam against Pseudomonas aeruginosa isolates obtained from patients in Canadian hospitals in the CANWARD study, 2007 to 2012. Antimicrob. Agents Chemother. 57:5707-5709. http://dx.doi.org/10.1128/AAC.01404-13.
14. Moya B, Zamorano L, Juan C, Perez JL, Ge Y, Oliver A. 2010. Activity of a new cephalosporin, CXA-101 (FR264205), against β-lactam-resistant Pseudomonas aeruginosa mutants selected in vitro and after antipseudomonal treatment of intensive care unit patients. Antimicrob. Agents Chemother. 54:1213-1217. http://dx.doi.org/10.1128/AAC.01104-09.
15. Takeda S, Ishii Y, Hatano K, Tateda K, Yamaguchi K. 2007. Stability of FR264205 against AmpC β-lactamase of Pseudomonas aeruginosa. Int. J. Antimicrob. Agents 30:443-445. http://dx.doi.org/10.1016/j.ijantimicag.2007.05. 019. (Pubitemid 47498958)
16. Craig WA, Andes DR. 2013. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum β-lactamases, in the thighs of neutropenic mice. Antimicrob. Agents Chemother. 57:1577-1582. http://dx.doi.org/10.1128/AAC.01590-12.
17. Snydman DR, McDermott LA, Jacobus NV. 2014. Activity of ceftolozane-tazobactam against a broad spectrum of recent clinical anaerobic isolates. Antimicrob. Agents Chemother. 58:1218-1223. http://dx.doi.org/10.1128/ AAC.02253-13.
18. Lucasti C, Hershberger E, Miller B, Yankelev S, Steenbergen J, Friedland I, Solomkin. 2013. A multicenter, double-blind, randomized, phase 2 study to assess the safety and efficacy of ceftolozane/tazobactam (TOL/ TAZ) plus metronidazole (MTZ) compared to meropenem (MER) in adult patients with complicated intra-abdominal infections (cIAI), poster K-1709. 53rd Annu. Intersci. Conf. Antimicrob. Agents Chemother., 10-13 September 2013, Denver, CO.
19. AstraZeneca Pharmaceuticals. 2013. Merrem i.v. prescribing information. AstraZeneca Pharmaceuticals LP, Wilmington, DE. http://www1.astrazeneca-us.com/ pi/merremiv.pdf.
20. Miller B, Hershberger E, Benziger D, Trinh M, Friedland I. 2012. Pharmacokinetics and safety of intravenous ceftolozane-tazobactam in healthy adult subjects following single and multiple ascending doses. Antimicrob. Agents Chemother. 56:3086-3091. http://dx.doi.org/10.1128/AAC.06349-11.
21. Hershberger E, Mouksassi M, Steenbergen J, Benziger D, Fenneteau F, Marier JF, Friedland I. 2011. CXA-101/tazobactam probability of target attainment using population pharmacokinetic analysis, poster P1520. 21st Eur. Congr. Clin. Microbiology and Infectious Diseases and 27th International Congress of Chemother., Milan, Italy, 7-10 May 2011.
22. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing, 15th informational supplement. M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
23. Clopper CJ, Pearson ES. 1934. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 26:404-413. http://dx.doi.org/10.1093/biomet/26.4.404.
24. Lucasti C, Jasovich A, Umeh O, Jiang J, Kaniga K, Friedland I. 2008. Efficacy and tolerability of IV doripenem versus meropenem in adults with complicated intra-abdominal infection: a phase III, prospective, multicenter, randomized, double-blind, noninferiority study. Clin. Ther. 30:868-883. http://dx.doi.org/10.1016/j.clinthera.2008.04.019. (Pubitemid 351799866)
25. Lucasti C, Popescu I, Ramesh MK, Lipka J, Sable C. 2013. Comparative study of the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem in the treatment of complicated intra-abdominal infections in hospitalized adults: results of a randomized, double-blind, phase II trial. J. Antimicrob. Chemother. 68:1183-1192. http://dx.doi.org/10.1093/jac/dks523.
26. Qvist N, Warren B, Leister-Tebbe H, Zito ET, Pedersen R, McGovern PC, Babinchak T. 2012. Efficacy of tigecycline versus ceftriaxone plus metronidazole for the treatment of complicated intra-abdominal infections: results from a randomized, controlled trial. Surg. Infect. (Larchmt.) 13:102-109. http://dx.doi.org/10.1089/sur.2011.048.
27. Hawser SP, Badal RE, Bouchillon SK, Hoban DJ, Biedenbach DJ, Canton R, Paterson DL. 2013. Monitoring the global in vitro activity of ertapenem against Escherichia coli from intra-abdominal infections: SMART 2002-2010. Int. J. Antimicrob. Agents. 41:224-228. http://dx.doi.org/10.1016/j.ijantimicag.2012.10. 014.
28. Rodriguez-Bano J, Navarro MD, Retamar P, Picon E, Pascual A. 2012. Beta-lactam/beta-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin. Infect. Dis. 54:167-174. http://dx.doi.org/10.1093/cid/cir790.
29. Paterson DL, Bonomo RA. 2005. Extended-spectrum beta-lactamases: a clinical update. Clin. Microbiol. Rev. 18:657-686. http://dx.doi.org/10.1128/ CMR.18.4.657-686.2005.
30. Babinchak T, Ellis-Grosse E, Dartois N, Rose GM, Loh E. 2005. The efficacy and safety of tigecycline for the treatment of complicated intra-abdominal infections: analysis of pooled clinical trial data. Clin. Infect. Dis. 41(Suppl 5):S354-S367. http://dx.doi.org/10.1086/431676. (Pubitemid 41170382)
31. Solomkin JS, Yellin AE, Rotstein OD, Christou NV, Dellinger EP, Tellado JM, Malafaia O, Fernandez A, Choe KA, Carides A, Satishchandran V, Teppler H. 2003. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a dou-ble- blind, randomized comparative phase III trial. Ann. Surg. 237:235- 245. http://dx.doi.org/10.1097/01.SLA. 0000048551.32606.73.